绥美凯有用吗？

The State Food and Drug Administration (CFDA) has approved the entry of a new compound preparation for AIDS treatment (chemical name: Dolutea Paramid Tablets) into China. As an innovative single-pill compound preparation with obvious clinical therapeutic advantages, Suimeikai can provide great convenience for the treatment of AIDS patients and has received priority review and approval from the State Food and Drug Administration. It is understood that Suimeike is an innovative HIV treatment drug for ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerability, high resistance barrier and few drug interactions. It can be taken once a day, one tablet at a time, significantly reducing the medication burden of AIDS patients, thereby increasing patients' medication compliance and significantly improving their quality of life.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the drug safety of Suimeike, which is based on DTG integrase inhibitors, has proven to be controllable. Generally speaking, it has four main advantages: 1. Excellent efficacy and significant viral suppression effect; 2. The three drugs are equivalent, and both newly-treated and previously treated patients have high drug resistance barriers, which is not easy to lead to drug resistance; 3. It is easy to take, only needs to be taken once a day, and there is no need to consider food effects; 4. The drug has low side effects and good tolerance, and the discontinuation rate due to drug side effects is low; 5. The metabolic pathway has few interactions with other drugs.